Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generium Pharmaceutical

https://www.generium.ru/en/

Latest From Generium Pharmaceutical

Selexis And Generium Launch Omalizumab Biosimilar In Russia

Selexis and Generium have claimed the launch of an omalizumab biosimilar in Russia, with their Genolar version of Xolair marking the third biosimilar to be launched by the pair following development with Selexis’ SUREtechnology platform.

Biosimilars Launches
See All

Company Information

  • Industry
  • Biotechnology
  • Contract Manufacturing Organization
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • International Biotechnology Center (IBC) Generium, Generium JSC, AO Generium
UsernamePublicRestriction

Register